Source: International Congress 2015 – IPF: clinical aspects
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Yong hyun Kim (Bucheon, Gyeonggi-do, Republic of Korea), Yong Hyun Kim, Jun Pyo Myong, Soon Seog Kwon, Kihoon Park. The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea. Eur Respir J 2015; 46: Suppl. 59, 2035

Member's Comments

No comment yet.

Related content which might interest you: Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Idiopathic pulmonary fibrosis: classification, epidemiology, course and prognosis Source: International Congress 2016 – Russia Session Year: 2016 Incidence and prevalence of IPF in an insurance claims database: Assessing accuracy using medical records Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 A prothrombotic state is associated with increased mortality in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP) Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Occupational risk factors and idiopathic pulmonary fibrosis. A case-control study Source: Annual Congress 2007 - The air we breathe at home and at work Year: 2007 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in Eastern Finland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Tuberculosis in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013